Cargando...
Opening the door to follow-on proteins?
When the FDA approved the follow-on protein Omnitrope in May, it gave generic drug makers the wedge they were hoping for. With pressure building in Washington, did Omnitrope push the door open – or was it just an anomaly?
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioCommunications LLC
2006
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3571050/ https://ncbi.nlm.nih.gov/pubmed/23424385 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|